297 related articles for article (PubMed ID: 23840043)
1. Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery.
Kalams SA; Parker SD; Elizaga M; Metch B; Edupuganti S; Hural J; De Rosa S; Carter DK; Rybczyk K; Frank I; Fuchs J; Koblin B; Kim DH; Joseph P; Keefer MC; Baden LR; Eldridge J; Boyer J; Sherwat A; Cardinali M; Allen M; Pensiero M; Butler C; Khan AS; Yan J; Sardesai NY; Kublin JG; Weiner DB;
J Infect Dis; 2013 Sep; 208(5):818-29. PubMed ID: 23840043
[TBL] [Abstract][Full Text] [Related]
2. DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8
Li SS; Kochar NK; Elizaga M; Hay CM; Wilson GJ; Cohen KW; De Rosa SC; Xu R; Ota-Setlik A; Morris D; Finak G; Allen M; Tieu HV; Frank I; Sobieszczyk ME; Hannaman D; Gottardo R; Gilbert PB; Tomaras GD; Corey L; Clarke DK; Egan MA; Eldridge JH; McElrath MJ; Frahm N;
Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28931520
[TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial.
Elizaga ML; Li SS; Kochar NK; Wilson GJ; Allen MA; Tieu HVN; Frank I; Sobieszczyk ME; Cohen KW; Sanchez B; Latham TE; Clarke DK; Egan MA; Eldridge JH; Hannaman D; Xu R; Ota-Setlik A; McElrath MJ; Hay CM;
PLoS One; 2018; 13(9):e0202753. PubMed ID: 30235286
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.
Graham BS; Koup RA; Roederer M; Bailer RT; Enama ME; Moodie Z; Martin JE; McCluskey MM; Chakrabarti BK; Lamoreaux L; Andrews CA; Gomez PL; Mascola JR; Nabel GJ;
J Infect Dis; 2006 Dec; 194(12):1650-60. PubMed ID: 17109336
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults.
Kalams SA; Parker S; Jin X; Elizaga M; Metch B; Wang M; Hural J; Lubeck M; Eldridge J; Cardinali M; Blattner WA; Sobieszczyk M; Suriyanon V; Kalichman A; Weiner DB; Baden LR;
PLoS One; 2012; 7(1):e29231. PubMed ID: 22242162
[TBL] [Abstract][Full Text] [Related]
6. Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation.
Otten GR; Schaefer M; Doe B; Liu H; Megede JZ; Donnelly J; Rabussay D; Barnett S; Ulmer JB
Vaccine; 2006 May; 24(21):4503-9. PubMed ID: 16181711
[TBL] [Abstract][Full Text] [Related]
7. A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults.
Mpendo J; Mutua G; Nyombayire J; Ingabire R; Nanvubya A; Anzala O; Karita E; Hayes P; Kopycinski J; Dally L; Hannaman D; Egan MA; Eldridge JH; Syvertsen K; Lehrman J; Rasmussen B; Gilmour J; Cox JH; Fast PE; Schmidt C
PLoS One; 2015; 10(8):e0134287. PubMed ID: 26252526
[TBL] [Abstract][Full Text] [Related]
8. SIV antigen-specific effects on immune responses induced by vaccination with DNA electroporation and plasmid IL-12.
Lindsay RW; Ouellette I; Arendt HE; Martinez J; DeStefano J; Lopez M; Pavlakis GN; Chiuchiolo MJ; Parks CL; King CR
Vaccine; 2013 Oct; 31(42):4749-58. PubMed ID: 23954384
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector.
Catanzaro AT; Koup RA; Roederer M; Bailer RT; Enama ME; Moodie Z; Gu L; Martin JE; Novik L; Chakrabarti BK; Butman BT; Gall JG; King CR; Andrews CA; Sheets R; Gomez PL; Mascola JR; Nabel GJ; Graham BS;
J Infect Dis; 2006 Dec; 194(12):1638-49. PubMed ID: 17109335
[TBL] [Abstract][Full Text] [Related]
10. HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.
Nilsson C; Hejdeman B; Godoy-Ramirez K; Tecleab T; Scarlatti G; Bråve A; Earl PL; Stout RR; Robb ML; Shattock RJ; Biberfeld G; Sandström E; Wahren B
PLoS One; 2015; 10(6):e0131748. PubMed ID: 26121679
[TBL] [Abstract][Full Text] [Related]
11. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania.
Bakari M; Aboud S; Nilsson C; Francis J; Buma D; Moshiro C; Aris EA; Lyamuya EF; Janabi M; Godoy-Ramirez K; Joachim A; Polonis VR; Bråve A; Earl P; Robb M; Marovich M; Wahren B; Pallangyo K; Biberfeld G; Mhalu F; Sandström E
Vaccine; 2011 Oct; 29(46):8417-28. PubMed ID: 21864626
[TBL] [Abstract][Full Text] [Related]
12. Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine.
Kanagavelu SK; Snarsky V; Termini JM; Gupta S; Barzee S; Wright JA; Khan WN; Kornbluth RS; Stone GW
Vaccine; 2012 Jan; 30(4):691-702. PubMed ID: 22146759
[TBL] [Abstract][Full Text] [Related]
13. The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection.
Jacobson JM; Zheng L; Wilson CC; Tebas P; Matining RM; Egan MA; Eldridge J; Landay AL; Clifford DB; Luetkemeyer AF; Tiu J; Martinez AL; Janik J; Spitz TA; Hural J; McElrath J; Frahm N;
J Acquir Immune Defic Syndr; 2016 Feb; 71(2):163-71. PubMed ID: 26761518
[TBL] [Abstract][Full Text] [Related]
14. Robust antibody and cellular responses induced by DNA-only vaccination for HIV.
De Rosa SC; Edupuganti S; Huang Y; Han X; Elizaga M; Swann E; Polakowski L; Kalams SA; Keefer MC; Maenza J; Lu Y; Wise MC; Yan J; Morrow MP; Khan AS; Boyer JD; Humeau L; White S; Pensiero M; Sardesai NY; Bagarazzi ML; Weiner DB; Ferrari G; Tomaras GD; Montefiori DC; Corey L; McElrath MJ;
JCI Insight; 2020 Jul; 5(13):. PubMed ID: 32437332
[TBL] [Abstract][Full Text] [Related]
15. An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection.
Hemachandra A; Puls RL; Sirivichayakul S; Kerr S; Thantiworasit P; Ubolyam S; Cooper DA; Emery S; Phanuphak P; Kelleher A; Ruxrungtham K
Hum Vaccin; 2010 Oct; 6(10):835-40. PubMed ID: 20864808
[TBL] [Abstract][Full Text] [Related]
16. An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers.
Van Braeckel E; Bourguignon P; Koutsoukos M; Clement F; Janssens M; Carletti I; Collard A; Demoitié MA; Voss G; Leroux-Roels G; McNally L
Clin Infect Dis; 2011 Feb; 52(4):522-31. PubMed ID: 21208909
[TBL] [Abstract][Full Text] [Related]
17. The Safety and Immunogenicity of GTU
Haidari G; Day S; Wood M; Ridgers H; Cope AV; Fleck S; Yan C; Reijonen K; Hannaman D; Spentzou A; Hayes P; Vogt A; Combadiere B; Cook A; McCormack S; Shattock RJ
Front Immunol; 2019; 10():2911. PubMed ID: 31921170
[TBL] [Abstract][Full Text] [Related]
18. Enhanced immunogenicity of an HIV-1 DNA vaccine delivered with electroporation via combined intramuscular and intradermal routes.
Mann JF; McKay PF; Fiserova A; Klein K; Cope A; Rogers P; Swales J; Seaman MS; Combadiere B; Shattock RJ
J Virol; 2014 Jun; 88(12):6959-69. PubMed ID: 24719412
[TBL] [Abstract][Full Text] [Related]
19. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).
Kibuuka H; Kimutai R; Maboko L; Sawe F; Schunk MS; Kroidl A; Shaffer D; Eller LA; Kibaya R; Eller MA; Schindler KB; Schuetz A; Millard M; Kroll J; Dally L; Hoelscher M; Bailer R; Cox JH; Marovich M; Birx DL; Graham BS; Michael NL; de Souza MS; Robb ML
J Infect Dis; 2010 Feb; 201(4):600-7. PubMed ID: 20078213
[TBL] [Abstract][Full Text] [Related]
20. Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials.
Moodie Z; Walsh SR; Laher F; Maganga L; Herce ME; Naidoo S; Hosseinipour MC; Innes C; Bekker LG; Grunenberg N; Mann P; Yu C; deCamp AC; Miner MD; Yates NL; Heptinstall J; Mkhize NN; Dintwe O; Frahm N; Cohen KW; Allen M; Hutter J; Wagner R; Pantaleo G; McElrath MJ; Tomaras GD; Morris L; Montefiori DC; Andersen-Nissen E; Gray GE; Gilbert PB; Kublin JG;
PLoS Med; 2020 May; 17(5):e1003117. PubMed ID: 32442195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
